Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 18/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217519 | 0.91 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL8621371 | 0.84 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL7215696 | 0.83 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL7222478 | 0.80 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL7071347 | 0.78 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL7560082 | 0.77 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL7557332 | 0.73 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL7981205 | 0.73 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL8619340 | 0.72 | CRHR1 (0.79) | CRHR1 | |
| SCHEMBL7555458 | 0.72 | CRHR1 (0.37) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2002-08-15 | — | — | US | claimed |
| US-6670371-B2 | Antagonists of Corticotropin-Releasing Factor | NEUROGEN CORPORATION | 2003-12-30 | — | — | US | disclosed |
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6355651-B1 | AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6133282-A | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| US-5955613-A | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1998045295-A1 | CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | CRHR1, CRH, CRHR2 | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.